Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond
about
Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?InsomniaNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?An overview of the synthetic routes to the best selling drugs containing 6-membered heterocyclesImplementation of Sleep and Circadian Science: Recommendations from the Sleep Research Society and National Institutes of Health WorkshopAlterations in brain-derived neurotrophic factor in the mouse hippocampus following acute but not repeated benzodiazepine treatmentGABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism.Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors.GABAA receptor drugs and neuronal plasticity in reward and aversion: focus on the ventral tegmental areaUrinary diazepam metabolite distribution in a chronic pain population.Anticonflict and reinforcing effects of triazolam + pregnanolone combinations in rhesus monkeys.Progesterone effects on the discriminative stimulus, subjective and performance effects of triazolam in healthy, premenopausal womenNeurosteroids as neuromodulators in the treatment of anxiety disorders.Anxiolytic-like effects of compound zhi zhu xiang in rats.Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.Polydrug abuse: a review of opioid and benzodiazepine combination useAntagonism of triazolam self-administration in rhesus monkeys responding under a progressive-ratio schedule: In vivo apparent pA2 analysis.Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic painReinforcing effects of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys.The Impact of Benzodiazepine Use on Mortality Among Polysubstance Users in Vancouver, Canada.The neuropharmacology of the age-old sedative/hypnotic, ethanolPsychological treatment of hypnotic-dependent insomnia in a primarily older adult sample.Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension.Benzodiazepines revisited--will we ever learn?The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.Increasing availability of benzodiazepines among people who inject drugs in a Canadian setting.Emergency department visits involving benzodiazepines and non-benzodiazepine receptor agonists.The abuse liability of the NMDA receptor antagonist-benzodiazepine (tiletamine-zolazepam) combination: evidence from clinical case reports and preclinical studies.Long-term Use of Z-Hypnotics and Co-medication with Benzodiazepines and Opioids.Understanding sleep-wake mechanisms and drug discovery.Role of gamma-aminobutyric acid type A (GABAA) receptor subtypes in acute benzodiazepine physical dependence-like effects: evidence from squirrel monkeys responding under a schedule of food presentation.Duration of treatment and activation of α1-containing GABAA receptors variably affect the level of anxiety and seizure susceptibility after diazepam withdrawal in rats.Alprazolam withdrawal delirium and brief reversible psychosis: a case report.βCCT, an antagonist selective for α(1)GABA(A) receptors, reverses diazepam withdrawal-induced anxiety in rats.Metabolism, pharmacokinetics and excretion of the GABA(A) receptor partial agonist [(14)C]CP-409,092 in rats.[Benzodiazepin addiction: a silent addiction among older people].A Single Amino Acid Residue at Transmembrane Domain 4 of the α Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors.The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat.
P2860
Q21296639-61DFA3F5-8AA3-4FA5-AA3D-2D62C82493CBQ24632498-00957E32-0919-4538-876F-62F1BF5B5D5DQ28277165-630B3AE8-7762-4B0C-9332-CF6C941355BCQ28301501-9C928F62-4DA0-4419-A985-B8A67EBD8E1CQ28393831-B1781739-75AA-44BD-9F67-C650F0440933Q28537823-D7DB6D6B-8A16-42E1-9F05-64BC4910B4B1Q30421260-4C563E99-6248-4490-8DA4-D758695D7F80Q30580823-10AE6618-0C4E-4BB2-B115-7A916819695EQ34513926-9396E6B9-5FEE-45A9-98DD-C5EA074094E8Q34569409-C1C570FD-6DDE-42CE-BC51-31E2E4498737Q34659504-0A9E8F78-650D-429B-9EAD-ABD809F0D0D0Q35003075-6D0C032E-7FEE-4835-8A5F-AB1CEBA11622Q35212010-690D8D3B-7C01-4D24-917D-4F6245D4D42FQ35971707-F1AA4846-E7F6-4DC0-8146-DB83899996FDQ36011625-CCC4F019-E610-40AA-9A93-BEAB221185D1Q36054271-92F36D29-154B-4A1D-BCF5-87CC0DD2B507Q36266246-E328BFD7-25B6-4405-AFF8-7FE4D01F0996Q36421449-75E59C3A-B874-4AAE-AC57-C5C371A7C33AQ36533714-2BC2C4C1-41FE-41BE-B330-31FCA6A77F4BQ36592958-FB8855EC-BB88-438A-8E5A-3D73D1DE9056Q36775238-A8CC278C-77E1-4C24-A25E-E706FA74640FQ36906777-68AE068A-7550-4D6D-9443-C3CFD7DC53EAQ37011246-C9A8D95F-18C6-45CF-92C0-DB11C95C158CQ37337370-0ADD7549-322C-4CC7-A411-AC33CD74625DQ37670034-270B4229-7DF4-4423-8D1C-8D1E52C8CFD2Q37895716-1E0A8D25-E597-4218-BE99-7BAF20021A62Q38190472-3AEA2A3C-E16B-4C65-BFE5-FD1415D93A5AQ38669904-A4883E10-D943-445B-A42F-17F583508F8AQ38801507-B6206133-6196-46F7-93C1-B2EC0EE9D650Q38875939-1BE74367-AFAB-4EB0-A65B-7A0FA1E3BBB1Q39311482-7A68E87E-DE42-4400-9FDD-EDAF9FB41DEBQ39311775-F6533EC5-6528-4050-BCC1-D7A0F211FFCAQ40165591-209271AE-17A4-4F76-9A92-0E49D84DAE13Q40983182-E528AF20-36FA-422A-B36E-FCE12055638CQ41943782-946FDEFB-4C2C-46D7-9FC9-FCD862804058Q42044694-7263A47A-74ED-40CE-8A06-930B07A9C59EQ43119943-46FC6F6C-0546-4317-9D67-DC3F8A39E1E1Q43819387-D0A2F793-5BBD-4135-B193-4D016DE7BCAFQ45061898-B5CB2ED8-7945-4B55-9F61-6C4851E7B2C5Q45997372-38F9BB19-F6A5-446C-B094-ECE7A54A2C53
P2860
Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Abuse and dependence liability ...... receptor modulation and beyond
@ast
Abuse and dependence liability ...... receptor modulation and beyond
@en
Abuse and dependence liability ...... receptor modulation and beyond
@nl
type
label
Abuse and dependence liability ...... receptor modulation and beyond
@ast
Abuse and dependence liability ...... receptor modulation and beyond
@en
Abuse and dependence liability ...... receptor modulation and beyond
@nl
prefLabel
Abuse and dependence liability ...... receptor modulation and beyond
@ast
Abuse and dependence liability ...... receptor modulation and beyond
@en
Abuse and dependence liability ...... receptor modulation and beyond
@nl
P2860
P1476
Abuse and dependence liability ...... receptor modulation and beyond
@en
P2093
James K Rowlett
Stephanie C Licata
P2860
P356
10.1016/J.PBB.2008.01.001
P407
P577
2008-07-01T00:00:00Z